Key dosing points from the study: Dose range: 200500 mcg per session (individual variation based on severity and body weight) Frequency: 23 sessions per week during the active treatment phase Duration: 48 weeks of active treatment Route: Local subcutaneous injection proximal to the affected joint Concurrent therapy: Most patients continued physical therapy alongside BPC-157 treatment The combination of local administration and physical therapy aligns with the hypothesis that BPC-157 accelerates structural repair while functional loading (exercise) guides proper tissue remodeling
Injectable/systemic human data is very limited
Setria L-Glutathione
It was shown before that treatment with a mitochondria-targeted analog of CoQH2 (mitoCoQH2), protected DHODH knockout cells against mitochondrial lipid peroxidation and ferroptosis induced by GPX4 inhibitors, i.e., RSL3 and ML162 19
Patients with GPX4 overexpression had a reduced 5-year OS of 73% compared to 97% in patients with normal GPX4 expression (HR 2.95
This TCA cycle suppression results in a large decrease in ATP, which adversely affects all ATP-dependent proteins, including those involved in nutrient transport, mobilization, and uptake, leading to mouse death